Luveniq Advisory Committee: Renal Side Effects May Be Key Issue With Immunosuppressant
This article was originally published in The Pink Sheet Daily
Executive Summary
Lux Biosciences' Luveniq (voclosporin) for uveitis will undergo review by FDA's Dermatologic and Ophthalmic Drugs Advisory Committee on June 28.
You may also be interested in...
FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial
Lux Biosciences will have to do another clinical trial - on top of three already completed Phase III studies - for FDA to consider approving its uveitis treatment Luveniq (voclosporin), the agency said in a "complete response" letter announced Aug. 4
FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial
Lux Biosciences will have to do another clinical trial - on top of three already completed Phase III studies - for FDA to consider approving its uveitis treatment Luveniq (voclosporin), the agency said in a "complete response" letter announced Aug. 4
FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial
In a "complete response" letter following the last-minute cancellation of an advisory committee review in June, FDA asks the biotech to do an additional confirmatory study.